Research Department

Medical Oncology/Hematologic Neoplasia

Interests

Multiple myeloma, Stem cell transplantation

Area of Research

Chemical Biology and Cancer Biology

Biography

Dr. Bradner received his MD from The University of Chicago in 1999. He completed his postgraduate training in Internal Medicine at Brigham and Women's Hospital, followed by a fellowship in Medical Oncology and Hematology at Dana-Farber Cancer Institute and Brigham and Women's Hospital. In 2005, he joined Dana-Farber and is currently a member of the Hematologic Malignancies staff.

Board Certification
Medicine, 2002
Medical Oncology, 2005
Hematology, 2006

Residency
Brigham & Women's Hospital, Medicine, 1999-2002

Fellowship
Dana-Farber Cancer Institute, Hematology-Oncology, 2002-2005

Medical School
University of Chicago-Pritzker School of Medicine, Chicago, IL, 1999 

Recent Awards

• Damon Runyon-Rachleff Innovation Award, 2010
• Smith Family Award for Excellence in Biomedical Research, 2010
• Rising Star Award, Dunkin Donuts, 2007
• Fellow Scholar Award, American Society of Hematology, 2006
• Distinguished Excellence in Teaching Award, Brigham & Women's Hospital, 2005
• Golden Hammer Teaching Award, Harvard Medical School, 2002
• Bok Teaching Award, 1995

Research

The focus of the Bradner laboratory concerns the discovery, optimization and characterization of small-molecule modulators of gene regulatory pathways. Simply stated, we strive to develop prototype drugs which act to turn off growth genes in cancer cells by inhibiting master regulators of cell division and cellular memory. The clinical objective of our group is to deliver new therapeutics for human clinical investigation in hematologic diseases.

Select Publications

• Direct inhibition of the NOTCH transcription factor complex. Moellering RE, Cornejo M, Davis TN, Del Bianco C, Aster JC, Blacklow SC, Kung AL, Gilliland DG, Verdine GL, Bradner JE. Nature. 2009 Nov 12;462(7270):182-8.
• Synthesis and conformation-activity relationships of the peptide isosteres of FK228 and largazole. Bowers AA, Greshock TJ, West N, Estiu G, Schreiber SL, Wiest O, Williams RM, Bradner JE. J Am Chem Soc. 2009 Mar 4;131(8):2900-5.
• Selective inhibition of BET bromodomains. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I, Philpott M, Munro S, McKeown MR, Wang Y, Christie AL, West N, Cameron MJ, Schwartz B, Heightman TD, La Thangue N, French CA, Wiest O, Kung AL, Knapp S, Bradner JE. Nature. 2010 Sep 24. [Epub ahead of print]
• Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease. Bradner JE, Mak R, Tanguturi SK, Mazitschek R, Haggarty SJ, Ross K, Chang CY, Bosco J, West N, Morse E, Lin K, Shen JP, Kwiatkowski NP, Gheldof N, Dekker J, DeAngelo DJ, Carr SA, Schreiber SL, Golub TR, Ebert BL. Proc Natl acad Sci USA. 2010 Jul 13;107(28):12617-22. Epub 2010 Jun 28.
• Chemical phylogenetics of histone deacetylases. Bradner JE, West N, Grachan ML, Greenberg EF, Haggarty SJ, Warnow T, Mazitschek R. Nat Chem Biol. 2010 Mar;6(3):238-243. Epub 2010 Feb 7.